Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 357-364

  Dennison, Jennifer B ^a,c   Renbarger, Jamie L ^a   Walterhouse, David O ^b   Jones, David R ^a   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Tandem mass spectrometry; Vincristine; Vincristine metabolism

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A; DACTINOMYCIN; DICHLOROMETHANE; FORMIC ACID; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE; WATER; ANTINEOPLASTIC AGENT;

ACCURACY; ACIDIFICATION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG METABOLISM; DRUG PURIFICATION; DRUG QUALITY; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PARTICLE SIZE; PLASMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; ROOM TEMPERATURE; STANDARD; TANDEM MASS SPECTROMETRY; BLOOD; CALIBRATION; CHILD; HALF LIFE TIME; METABOLISM; PROSPECTIVE STUDY; QUALITY CONTROL; REPRODUCIBILITY; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALIBRATION; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; PROSPECTIVE STUDIES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RHABDOMYOSARCOMA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY; VINBLASTINE; VINCRISTINE;

EID: 47249104198     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31816b92c9     Document Type: Article

References (21)

1. Crom W, de Graaf S, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphoblastic leukemia. J Pediatr. 1994;125:642-649.
2. McCune J, Lindley C. Appropriateness of maximum dose guidelines for vincristine. Am J Health Syst Pharm. 1997;54:1755-1758.
3. Pollock B, DeBaun M, Camitta B, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 2000;18:813-823.
4. Villikka K, Kivisto K, Maenpaa H, et al. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999;66:589-593.
5. Fedeli L, Colozza M, Boschetti E, et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer. 1989;64:1805-1811.
6. Chan J. Pharmacokinetic drug interaction of vinca alkaloids: summary of case reports. Pharmacotherapy. 1998;18:1304-1307.
7. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317-1327.
8. Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007;321:553-563.
9. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
10. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5:243-272.
11. Schmidt MS, Huang R, Classon RJ, et al. Determination of vincristine in infant plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectroscopy. J Pharm Biomed Anal. 2006;41:540-543.
12. Skolnik JM, Barrett JS, Shi H, et al. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemother Pharmacol. 2006;57:458-464.
13. Nelson R. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol. 1982;10:115-127.
14. Sethi V, Jackson D, White D, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 1981;41:3551-3555.
15. Groninger E, Meeuwsen-de Boar T, Koopmans P, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2002;52:113-118.
16. Kellie SJ, Koopmans P, Earl J, et al. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer. 2004;100:2637-2643.
17. Favretto D, Piovan A, Filippini R, et al. Monitoring the production yields of vincristine and vinblastine in Catharanthus roseus from somatic embryogenesis. Semiquantitative determination by flow-injection electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2001;15:364-369.
18. Van Heugen JC, De Graeve J, Zorza G, et al. New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A. 2001;926:11-20.
19. Koopmans P, Gidding CE, de Graaf SS, et al. An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children. Ther Drug Monit. 2001;23: 406-409.
20. Guo P, Wang X, Zhou F, et al. Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;809: 273-278.
21. Ramirez J, Ogan K, Ratain M. Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Cancer Chemother Pharmacol. 1997;39:286-290.